10月17日 - ** 药物开发商Artiva ARTV.O股价盘前大涨102.5%，至5.57美元
** 该公司周四称美国FDA授予其细胞疗法AlloNK (link) 快速通道称号，用于治疗难治性类风湿性关节炎
** 美国 FDA 的 "快速通道 "标签旨在加快开发和审查治疗未满足医疗需求的严重疾病的药物
** 难治性类风湿性关节炎是一种慢性关节疾病
** 20 多名患者接受了 AlloNK 加抗体疗法的自身免疫试验，包括类风湿性关节炎和狼疮--ARTV
** 红斑狼疮是一种慢性自身免疫性疾病，人体免疫系统会错误地攻击自身组织和器官
** 公司称安全性数据将突出耐受性和易用性
** 截至收盘，股价下跌 ~73
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.